Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
atogepant + ubrogepant
- Development stage
- Phase 4
- Lead developer
- AbbVie
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
**Atogepant + ubrogepant** is a combination of two oral small molecule CGRP (calcitonin gene-related peptide) receptor antagonists, both used in the treatment of migraine. Atogepant is approved for the preventive treatment of episodic or chronic migraine, while ubrogepant is used for the acute treatment of migraine attacks. Both drugs function by blocking the CGRP receptor, thereby inhibiting CGRP-mediated nociception, vasodilation, and neurogenic inflammation involved in migraine pathophysiology. Clinical studies have shown that the combination is safe and well tolerated, with no clinically meaningful pharmacokinetic interactions or new safety signals reported for the combination versus individual agents in adults with history of migraine[1][3][5][7].
- Brand names
- none known for the combination
- Other names
- none known for the combination
02
Targets
Calcitonin gene-related peptide type 1 receptor
Beyond the preview
Go deeper on atogepant + ubrogepant.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on atogepant + ubrogepant.